SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following pivotal international approvals for its ANKTIVA cancer therapy in the EU and Saudi Arabia, complemented by robust revenue growth. The community is buzzing about the drug's global market expansion and potential as a chemotherapy-free cancer treatment, anticipating a substantial short squeeze.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending after its CagriSema weight-loss drug trial achieved 23% weight loss but missed its primary endpoint of non-inferiority compared to Eli Lilly's tirzepatide, causing a significant stock drop. The community is debating whether this market reaction is an overblown response to a minor efficacy difference, creating a buying opportunity, or if it signals a tougher competitive landscape against its rival.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is buzzing after securing FDA approval for BYSANTI, its new drug for bipolar I disorder and schizophrenia, a development the community sees as a significant re-rating catalyst due to its New Chemical Entity status and patent protection extending to 2044. This long-term exclusivity is fueling widespread speculation about potential buyout offers from major pharmaceutical companies and the stock's short squeeze potential, even as some investors eye commercial launch timelines and possible dilution.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors digest news of a significant stock sale filing from Trump's trust, fueling community discussions around potential dilution and the company's highly scrutinized financial viability. There is ongoing anticipation of upcoming reports and updates regarding a debated 'fusion deal' amidst concerns about its fundamental value.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

Enthusiasm for MoonLake Immunotherapeutics is surging following stellar Phase 2 S-OLARIS trial results for its lead drug sonelokimab in axial spondyloarthritis, with the community highlighting "best-in-class" efficacy, disease-modifying potential, strong financials, and anticipating further positive updates at its upcoming Investor Day.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera (ATOM) is trending as a recent direct stock offering at $5 sparks debate, with bulls viewing it as a strategic move to fund game-changing MST technology for AI and data centers, while bears voice skepticism over dilution given the company's pre-revenue status and historical performance.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as Novo Nordisk's recent obesity drug trial setback intensifies community speculation around a major acquisition or partnership, highlighting Viking's promising VK2735 asset as a crucial strategic fit for big pharma. Many believe the urgent need for a competitive GLP-1/GIP dual agonist in the booming metabolic market will force a significant deal and trigger a short squeeze.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to the FDA granting Priority Review for AXS-05 in Alzheimer's disease agitation, setting an April PDUFA date, alongside robust Q4 earnings and strong commercial growth for its CNS therapies. The community is highly optimistic about AXS-05's market potential and the company's trajectory towards cash flow positivity, further supported by multiple analyst upgrades and pipeline advancements.

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Arcellx Inc

Arcellx is trending as Gilead Sciences announced its acquisition for $7.8 billion, with the community focusing on the substantial premium and the strategic value of Arcellx's promising CAR T-cell therapy, anito-cel, which has shown strong clinical data for multiple myeloma.

20/20 Biolabs, Inc. engages in development and commercialization of proteomics product line. Its products include One Test, PAULA's Test and BioCheck Suspisious Powder Testing Kit. The company was founded by Jonathan Cohen in May 2000 and is headquartered in Gaithersburg, MD.

20/20 Biolabs Inc

AIDX is trending due to extreme post-IPO volatility, experiencing significant declines as community discussion points to a potential "pump and dump" for the newly public direct lister, also facing headwinds from a sector-wide downturn in the liquid biopsy space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Apple Inc. $AAPL Shares Sold by Amalgamated Bank

Amalgamated Bank trimmed its position in shares of Apple Inc. (NASDAQ:AAPL - Free Report) by 0.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned...

Allianz Asset Management GmbH Sells 152,208 Shares of Amalgamated Financial Corp. $AMAL

Allianz Asset Management GmbH reduced its position in shares of Amalgamated Financial Corp. (NASDAQ:AMAL - Free Report) by 60.4% during the 3rd quarter, according to its most recent 13F filing with...

Amalgamated Bank Acquires 1,643 Shares of Microsoft Corporation $MSFT

Amalgamated Bank boosted its holdings in Microsoft Corporation (NASDAQ:MSFT - Free Report) by 0.1% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The...

Amalgamated Financial (NASDAQ:AMAL) Hits New 1-Year High - Time to Buy?

Amalgamated Financial (NASDAQ:AMAL) Hits New 1-Year High - Still a Buy...

NVIDIA Corporation $NVDA Shares Acquired by Amalgamated Bank

Amalgamated Bank lifted its holdings in shares of NVIDIA Corporation (NASDAQ:NVDA - Free Report) by 0.1% during the 3rd quarter, according to its most recent 13F filing with the SEC. The...

AlphaQuest LLC Makes New Investment in Amalgamated Financial Corp. $AMAL

AlphaQuest LLC bought a new position in Amalgamated Financial Corp. (NASDAQ:AMAL - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and...

Is Ares Capital Stock Worth Owning Ahead of Q4 Earnings?

ARCC is set to post Q4 results, with a modest revenue growth forecast, flat EPS estimates and expense pressures as rate cuts weigh on sentiment.

Alphabet Inc. $GOOGL is Amalgamated Bank's 7th Largest Position

Amalgamated Bank decreased its stake in shares of Alphabet Inc. (NASDAQ:GOOGL - Free Report) by 0.2% during the third quarter, according to its most recent filing with the SEC. The institutional...

Ares Capital Slips 10.4% in 6 Months: Should You Still Buy the Stock?

ARCC shares fall 10.4% in six months as rate cuts squeeze yields, but robust originations, income growth and dividends test the bear case.

Do Options Traders Know Something About Amalgamated Financial Stock We Don't?

Investors need to pay close attention to Amalgamated Financial stock based on the movements in the options market lately.

Amalgamated Financial Corp. operates as a holding company for Amalgamated Bank. It offers commercial and retail banking, investment management, and trust custody segments. The company was founded in 1923 and is headquartered in New York, NY.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$0.99	--	--	N/A
Q4 '25	$0.90	$0.99	9.39%	BEAT
Q3 '25	$0.88	$0.91	4.00%	BEAT
Q2 '25	$0.87	$0.88	1.15%	BEAT
Q1 '25	$0.80	$0.88	10.00%	BEAT

AMAL
Amalgamated Financial Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest AMAL News

AMALAmalgamated Financial Corp